Evidence map›Paper›PMID 37191268›Full record

ArticleJournal of medicinal chemistry2023

Synthesis and Development of Highly Selective Pyrrolo[2,3-

Thomas Ihle Aarhus, Frithjof Bjørnstad, Camilla Wolowczyk, Kristin Uhlving Larsen, Line Rognstad, Trygve Leithaug, Anke Unger, Peter Habenberger, Alexander Wolf, Geir Bjørkøy and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Design and Synthesis of Pyridine-Based Pyrrolo[2,3-Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  3. Synthetic Routes to 2-aryl-1Molecules (Basel, Switzerland) · 2024
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Thomas Ihle AarhusDepartment of Materials Science & Engineering, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.
Frithjof BjørnstadDepartment of Materials Science & Engineering, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.
Camilla WolowczykDepartment of Biomedical Laboratory Science, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.
Kristin Uhlving LarsenSkogmo IndustriomrÅde, Industrivegen 50, N-7863 Overhalla, Norway.
Line RognstadDepartment of Chemistry, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.
Trygve LeithaugDepartment of Chemistry, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.
Anke UngerLead Discovery Center GmbH, Otto-Hahn-Straße 15, 44227 Dortmund, Germany.
Peter HabenbergerLead Discovery Center GmbH, Otto-Hahn-Straße 15, 44227 Dortmund, Germany.
Alexander WolfLead Discovery Center GmbH, Otto-Hahn-Straße 15, 44227 Dortmund, Germany.
Geir BjørkøyDepartment of Biomedical Laboratory Science, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.
Clare PridansUniversity of Edinburgh Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, U.K.
Jan EickhoffLead Discovery Center GmbH, Otto-Hahn-Straße 15, 44227 Dortmund, Germany.
Bert KleblLead Discovery Center GmbH, Otto-Hahn-Straße 15, 44227 Dortmund, Germany.
Bård H HoffDepartment of Chemistry, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.
Eirik SundbyDepartment of Materials Science & Engineering, Norwegian University of Science and Technology (NTNU), NO-7491 Trondheim, Norway.ORCID 0000-0002-4598-0239
Norwegian University of Science and Technology · NOLead Discovery Center (Germany) · DECentre for Inflammation Research · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colony-stimulating factor-1 receptor (CSF1R) is a receptor tyrosine kinase that controls the differentiation and maintenance of most tissue-resident macrophages, and the inhibition of CSF1R has been suggested as a possible therapy for a range of human disorders. Herein, we present the synthesis, development, and structure-activity relationship of a series of highly selective pyrrolo[2,3-

Indexed as

PyrimidinesReceptor Protein-Tyrosine KinasesHumansProtein Kinase InhibitorsStructure-Activity RelationshipProtein Kinase InhibitorsPyrimidinesReceptor Protein-Tyrosine Kinases

Identifiers

PMID37191268
PMCPMC10226129
OpenAlexW4376641041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.